The Need to Prioritize and Re-prioritize Palliative Care Options: Smoking Cessation as a Case-in-Point

  • Konstantinos Leventakos
  • Anna J. Schwecke
  • Erin Deering
  • Elizabeth Cathcart-Rake
  • Anna C. Sanh
  • Aminah JatoiEmail author
Palliative and Supportive Care (MP Davis, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Palliative and Supportive Care

Opinion statement

Palliative care in cancer patients requires a continuous reprioritization of effort. This review describes the need for this reprioritization and uses smoking cessation as a case-in-point. The treatment of patients with metastatic non-small cell lung cancer has changed dramatically in the past few years. Interestingly, patients who had previously smoked now have an improved prognosis—for a variety of reasons. This review discusses this last observation in detail and raises the question of how forcefully we should advise smoking cessation in patients with incurable metastatic non-small cell lung cancer.


Palliative care Smoking cessation Case-in-point 


Compliance With Ethical Standards

Conflict of Interest

Konstantinos Leventakos, Anna J. Schwecke, Erin Deering, Elizabeth Cathcart-Rake, Anna C. Sanh, and Aminah Jatoi declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Fulton JJ, LeBlanc TW, Cutson TM, et al. Integrated outpatient palliative care for patients with advanced cancer: a systematic review and meta-analysis. Palliat Med. 2018:1–12.Google Scholar
  2. 2.
    Temel JS, Greer JA, Muzikansy A, et al. Early palliative care for patients with metastatic non-small cell lung cancer. N Engl J Med. 2010;363:733–42.CrossRefGoogle Scholar
  3. 3.
    Barrera R, Shi W, Amar D, et al. Smoking and timing of cessation: impact of pulmonary complications after thoracotomy. Chest. 2005;127:1977–83.CrossRefGoogle Scholar
  4. 4.
    Tanner NT, Kanodra NM, Gebregziabher M, et al. The association between smoking abstinence and mortality in the National Lung Screening Trial. Am J Respir Crit Care Med. 2016;193:534–41.CrossRefGoogle Scholar
  5. 5.
  6. 6.
    Cataldo JK, Dubey S, Prochask JJ. Smoking cessation: an integral part of lung cancer treatment. Oncology. 2010;78:289–301.CrossRefGoogle Scholar
  7. 7.
    Lennes IT, Temel JS. Greer JA, et al. ASCO quality oncology practice initiative (QOPI) quality measures for smoking cessation and survival in metastatic non-small cell lung cancer. J Clin Oncol. 2011;29; abstract:6074.CrossRefGoogle Scholar
  8. 8.
    Li C, Marek M, Guclu SZ, et al. Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma. 2011; 2:52–62.Google Scholar
  9. 9.
    Kogure Y, Ando M, Saka H, et al. Histology and smoking status predict survival of patients with advanced non-small cell lung cancer. J Thorac Oncol. 2013;8:753–8.CrossRefGoogle Scholar
  10. 10.
    Desrichard A, Kuo F, Chowell D, et al. Tobacco smoking-associated alterations in the immune microenvironment of squamous cell carcinomas. J Natl Cancer Inst. 2018. 10.1093.Google Scholar
  11. 11••.
    Kim JH, Kim HS, Kim BJ. Prognostic value of smoking status in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Oncotarget 2017; 8:93149–93193,155. This meta-analysis points out the relationship between smoking and outcomes in patients who are receiving PD-L1 inhibitors.Google Scholar
  12. 12.
    Li B, Huang X, Fu L. Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis. Oncotargets Ther. 2018;11:3691–6.CrossRefGoogle Scholar
  13. 13•.
    Norum J, Nieder C. Tobacco smoking cessation and PD-L1 inhibitors in non-small cell lung cancer: a review of the literature. ESMO Open 2018; e000406. This paper points out the relationship between smoking and outcomes in patients who are receiving PD-L1 inhibitors.Google Scholar
  14. 14.
    Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung. N Eng J Med. 2015;372:2018–28.CrossRefGoogle Scholar
  15. 15.
    Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer. N Engl J Med. 2016;375:1823–33.CrossRefGoogle Scholar
  16. 16.
  17. 17.
    Halpern SD, Harhay MO, Saulsgiver K, et al. A pragmatic trial of e-cigarettes, incentives, and drugs for smoking cessation. N Engl J Med. 2018;378:2302–10.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Konstantinos Leventakos
    • 1
  • Anna J. Schwecke
    • 1
  • Erin Deering
    • 1
  • Elizabeth Cathcart-Rake
    • 1
  • Anna C. Sanh
    • 1
  • Aminah Jatoi
    • 1
    Email author
  1. 1.Department of Oncology, Mayo ClinicRochesterUSA

Personalised recommendations